Jardiance (empagliflozin) / Eli Lilly, Lupin, Boehringer Ingelheim - LARVOL DELTA

Empagliflozin might improve chronic inflammatory bowel diseases also in humans. (PubMed, Dig Liver Dis) - No abstract available

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

A rare case of gelatinous transformation of the bone marrow secondary to untreated hypothyroidism and congestive heart failure (ASH 2025) - "He was empirically treated with cefepime and azithromycin for presumed sepsis...He was started on levothyroxine 25 mcg, Jardiance 10 mg, and spironolactone 25 mg for HFpEF...Diagnosing GTBM requires a high index of suspicion and exclusion of other pancytopenia causes. Early recognition and treatment of the underlying disorder can reverse both GTBM and associated cytopenias."

Clinical • Aplastic Anemia • Cardiovascular • Congestive Heart Failure • Endocrine Disorders • Heart Failure • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Pituitary Gland Carcinoma • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Septic Shock • IL2

NiCl2/Hdipm-Catalyzed 2-OH-Selective Alkylation of Glycoside trans-Diols. (PubMed, Org Lett) - "This method was further applied to the efficient one-pot synthesis of both 2-OH and 3-OH glycosyl acceptors. Via the one-pot method, 2-O-methyl-empagliflozin (a potential anti-heart failure drug) was synthesized from empagliflozin with a total 76% yield."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Cureus) - "This benefit was consistent across most agents, including empagliflozin, canagliflozin, dapagliflozin, and sotagliflozin, while ertugliflozin showed a nonsignificant trend in the same direction. The results demonstrate that SGLT2 inhibitors confer clinically meaningful cardiorenal protection that is recognized to occur through mechanisms largely independent of glucose lowering, reinforcing their role as cornerstone agents in the management of T2DM. These findings highlight the importance of prioritizing SGLT2 inhibitors in contemporary diabetes care to reduce the global burden of heart failure (HF)."

Journal • Retrospective data • Review • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

EmFin-Nx: Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT (clinicaltrials.gov) - P2 | N=10 | Terminated | Sponsor: Jinling Hospital, China | N=100 ➔ 10 | Trial completion date: Dec 2027 ➔ Oct 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2027 ➔ Oct 2025; The patient enrollment rate is proceeding too slowly

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Chronic Kidney Disease • Genito-urinary Cancer • Kidney Cancer • Nephrology • Oncology • Renal Cell Carcinoma • Renal Disease • Solid Tumor

SGLT2i Therapy in Islet Transplantation (SIT) (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: University of Minnesota | Initiation date: Dec 2025 ➔ Mar 2026

Trial initiation date • Diabetes • Metabolic Disorders • Transplantation

Comparative Long-Term Cardiovascular Outcomes of Empagliflozin and Dapagliflozin in Heart Failure Patients After Coronary Revascularization: A Retrospective Cohort Study. (PubMed, J Clin Med) - " In this real-world cohort of revascularized HF patients, empagliflozin and dapagliflozin demonstrated comparable long-term cardiovascular outcomes, supporting a class effect of SGLT2 inhibitors in this high-risk population. Beyond pharmacologic comparison, age and AF emerged as dynamic predictors of cardiac MACE, highlighting the importance of longitudinal, time-dependent risk assessment in heart failure management following coronary revascularization."

Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Exploring the Real-World Effectiveness of Empagliflozin and Linagliptin Fixed-Dose Combination in Type 2 Diabetes Patients of Bangladesh: A Prospective Multi-Center Observational Study. (PubMed, Diabetes Metab Syndr Obes) - "The fixed-dose combination (FDC) of empagliflozin and linagliptin is a promising treatment for type 2 diabetes mellitus (T2DM), but real-world data from Bangladesh is limited. Empa/Lina (10/5) FDC demonstrated significant improvements in glycemic control, BMI, and blood pressure with a favorable safety profile in Bangladeshi patients with T2DM. These real-world findings support its use as an effective treatment option in this population."

Journal • Observational data • Real-world evidence • Diabetes • Hypoglycemia • Infectious Disease • Metabolic Disorders • Mycosis Fungoides • Nephrology • Type 2 Diabetes Mellitus

Effect of empagliflozin on human primary cardiomyocytes in a chemically induced hypoxia by CoCl2. (PubMed, Physiol Rep) - "After cobalt treatment, we didn't observe any protective effect of EMPA in cells affected by cobalt in various biological aspects, including miRNA expression, metabolomics, or viability. Although EMPA treatment was not able to propagate beneficial effects in the presence of cobalt, pretreatment of cells with EMPA indicated a potential cardioprotective effect associated with improving mitochondrial morphology."

Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Empagliflozin-Induced Liver Injury. (PubMed, Eur J Case Rep Intern Med) - "Drug-induced liver injury is a diagnosis of exclusion. Clinicians must rule out other causes, especially biliary obstruction, and use structured causality assessment tools to identify the offending drug.Empagliflozin and other sodium-glucose cotransporter 2 inhibitors can, in rare cases, cause liver injury. Monitoring liver function after initiating these drugs is advisable, particularly in patients with pre-existing liver disease.There is no specific treatment for idiosyncratic drug-induced liver injury. Prompt withdrawal of the offending and supportive care are usually sufficient for recovery."

Journal • Cardiovascular • Cholestasis • CNS Disorders • Diabetes • Fibrosis • Hepatology • Immunology • Inflammation • Liver Failure • Metabolic Disorders • Psychiatry • Schizophrenia • Type 2 Diabetes Mellitus

Heart failure with preserved ejection fraction: current insights and emerging therapeutic directions. (PubMed, Korean J Physiol Pharmacol) - "Empagliflozin significantly reduced the risk of cardiovascular death or heart failure hospitalization and dapagliflozin demonstrated comparable efficacy across regions. In numerous respects, the clinical and pathophysiological features of HFpEF in Asian populations diverge from those traditionally observed in Western cohorts. In this brief review, we will focus on therapeutics approved for HFpEF and agents currently under clinical trial, as well as the distinctive characteristics of HFpEF patients observed in Asia and the key considerations for future therapeutic development in this region."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Obesity

Empagliflozin and Dapagliflozin Outcomes in Heart Failure. (PubMed, JAMA Netw Open) - "In this cohort study of patients with HF, dapagliflozin and empagliflozin had similar clinical outcomes in HF management. Further research and clinical trials are necessary to validate these findings and inform clinical decision-making."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes (clinicaltrials.gov) - P=N/A | N=67 | Completed | Sponsor: Josip Juraj Strossmayer University of Osijek

Biomarker • New trial • Diabetes • Hepatology • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013-2024): a pharmacovigilance study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Dapagliflozin and empagliflozin accounted for more than 70% SAE reports, followed by canagliflozin (26.63%). SAE reports contributed to a large proportion of reports with SGLT2i in the FAERS database. SAE profile of individual SGLT2i varied."

Adverse events • Journal • Serious adverse event • Dermatology • Inflammation • Metabolic Disorders • Pancreatitis

Pharmacological prevention in cardio-oncology: from bench-to-bedside. (PubMed, Heart Fail Rev) - "Neurohormonal blockers, including ACE inhibitors, ARBs, and β-blockers, constitute the foundation of prevention, although their efficacy varies: combinations such as ACEi/ARB with βB yield mixed outcomes, whereas carvedilol offers antioxidant benefits beyond β-blockade. Sacubitril/valsartan (ARNI) has demonstrated improvements in global longitudinal strain and LVEF preservation in the SARAH trial, albeit with associated hypotension risks. Aldosterone antagonists show potential, with spironolactone preserving LVEF and diastolic function, though eplerenone has not shown significant effects. Statins present conflicting data; the STOP-CA trial supports atorvastatin for LVEF preservation, while the PREVENT and SPARE-HF trials found no benefit. Emerging evidence suggests sodium-glucose cotransporter-2 inhibitors (SGLT2i), such as dapagliflozin and empagliflozin, as promising agents, with preclinical and early clinical data indicating cardioprotection through metabolic..."

Journal • Review • Cardiovascular • Hypotension • Metabolic Disorders • Oncology • ICOS

The effect of sodium-glucose cotransporter-2 inhibitors on cardiovascular biomarkers and left ventricular function in patients with type 2 diabetes and concomitant cardiovascular disease. (PubMed, Endokrynol Pol) - "In patients with T2DM and established CVD, SGLT2i therapy was associated with significant improvements in left ventricular function and reductions in HF-related biomarkers, supporting the cardioprotective and nephroprotective effects of this drug class."

Biomarker • Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus • LGALS3

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=792 | Recruiting | Sponsor: Hoffmann-La Roche | N=580 ➔ 792 | Trial completion date: May 2028 ➔ Sep 2030 | Trial primary completion date: May 2028 ➔ Sep 2030

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PIK3CA

Bridging Cardiorenal and Hepatic Disease: The Emerging Role of SGLT2 Inhibitors in Cirrhosis. (PubMed, Cardiol Rev) - "A randomized, placebo-controlled trial in recurrent ascites demonstrated improved ascites control with dapagliflozin, although higher rates of infection and acute kidney injury were observed. Empagliflozin increased serum sodium in randomized trials of syndrome of inappropriate antidiuresis, supporting a plausible mechanism for correcting dilutional hyponatremia in cirrhosis. Preclinical findings regarding portal hypertension and encephalopathy are mixed and appear model-dependent."

Journal • Acute Kidney Injury • Cardiovascular • CNS Disorders • Fibrosis • Heart Failure • Hepatology • Hypertension • Immunology • Infectious Disease • Nephrology • Portal Hypertension • Renal Disease

Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator. (PubMed, Diabetologia) - P4 | "With similar glycaemic control, insulin sensitivity was higher and beta cell function improved during empagliflozin compared with insulin treatment, possibly due to a disinhibitory effect of lower insulin concentrations."

Journal • Diabetes • Endocrine Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Sodium-glucose cotransporter 2 inhibitor ameliorates thiazolidinedione-induced fluid retention through vascular leakage reduction in white adipose tissue. (PubMed, Diabetes Obes Metab) - "Our results suggest that SGLT2is protect against TZD-induced fluid retention by preserving vascular integrity in WAT, providing a viable therapeutic strategy to minimise TZD-associated side effects."

Journal • Diabetes • Metabolic Disorders • Obesity • CDH5

The sodium-glucose co-transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF receptor-β. (PubMed, Br J Pharmacol) - "The results highlight a novel mechanism underlying the beneficial effects of empagliflozin in PAH, through direct binding to the tyrosine kinase effector domain of PDGFRβ. This interaction inhibits PDGFRβ phosphorylation, offering new insights into therapeutic strategies for PAH."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • PDGFRB

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus (clinicaltrials.gov) - P3 | N=480 | Recruiting | Sponsor: EMS | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2026 ➔ Sep 2027 | Trial primary completion date: Mar 2026 ➔ Jul 2026

Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia. (clinicaltrials.gov) - P3 | N=228 | Recruiting | Sponsor: EMS | Trial completion date: Aug 2025 ➔ Sep 2027 | Trial primary completion date: Apr 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Methotrexate nephrotoxicity: a pragmatic approach. (PubMed, Curr Opin Nephrol Hypertens) - "Identification of emerging risk factors, advances in pharmacogenomics, and timely methotrexate monitoring, combined with patient-specific pharmacokinetic modeling, underscore the importance of personalized therapeutic strategies to reduce renal toxicity and DME."

Journal • Acute Kidney Injury • Nephrology • Oncology • Renal Disease

Physical association of NHE3 and SGLT2 mediated by accessory proteins in the renal proximal tubule. (PubMed, Am J Physiol Renal Physiol) - "Acute empagliflozin infusion altered the relative migration and colocalization of NHE3 with SGLT2 and MAP17 but did not disrupt overall complex integrity, supporting a conformational mechanism underlying its effects on NHE3. Together, these findings suggest that NHE3 and SGLT2 assemble into a multiprotein complex through PDZK1 and MAP17, providing mechanistic insight into the coordinated regulation of sodium, fluid, and glucose reabsorption in the proximal tubule."

Journal • PDZK1 • PDZK1IP1